Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Total Non-Current Liabilities (2023 - 2025)

Beta Bionics' Total Non-Current Liabilities history spans 3 years, with the latest figure at $39.6 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 37.77% year-over-year to $39.6 million; the TTM value through Dec 2025 reached $39.6 million, up 37.77%, while the annual FY2025 figure was $39.6 million, 37.77% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $39.6 million at Beta Bionics, up from $34.1 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $39.6 million in Q4 2025 and bottomed at $13.9 million in Q4 2023.
  • The 3-year median for Total Non-Current Liabilities is $28.0 million (2024), against an average of $27.9 million.
  • The largest annual shift saw Total Non-Current Liabilities skyrocketed 107.33% in 2024 before it soared 37.77% in 2025.
  • A 3-year view of Total Non-Current Liabilities shows it stood at $13.9 million in 2023, then skyrocketed by 107.33% to $28.7 million in 2024, then skyrocketed by 37.77% to $39.6 million in 2025.
  • Per Business Quant, the three most recent readings for BBNX's Total Non-Current Liabilities are $39.6 million (Q4 2025), $34.1 million (Q3 2025), and $27.3 million (Q2 2025).